Insulin sensitivity during combined androgen blockade for prostate cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 4, 2006, Pages 1305-1308

  Smith, Matthew R ^a   Lee, Hang ^a   Nathan, David M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BICALUTAMIDE; LEUPRORELIN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; GONADORELIN; INSULIN; LIPID; TESTOSTERONE;

AGED; ARTICLE; BODY COMPOSITION; BODY MASS; CLINICAL ARTICLE; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; INSULIN SENSITIVITY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROSTATE CANCER; ADIPOSE TISSUE; ADULT; ANTHROPOMETRY; BLOOD; DRUG EFFECT; DRUG POTENTIATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; METABOLISM; PHYSIOLOGY; PROSPECTIVE STUDY; PROSTATE TUMOR; RADIODENSITOMETRY; TREATMENT OUTCOME;

ADIPOSE TISSUE; ADULT; ANDROGEN ANTAGONISTS; ANTHROPOMETRY; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY COMPOSITION; DENSITOMETRY, X-RAY; GLUCOSE TOLERANCE TEST; GONADOTROPIN-RELEASING HORMONE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 33646029746     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2507     Document Type: Article

References (23)

1. Sharifi N, Gulley JL, Dahut WL 2005 Androgen deprivation therapy for prostate cancer. JAMA 294:238-244
2. Tayek JA, Heber D, Byerley LO, Steiner B, Rajfer J, Swerdloff RS 1990 Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism 39:1314-1319
3. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, Reimondo G, Mari M, Ardissone P, De Luca S, Fasolis G, Fontana D, Rossetti SR, Angeli A 2002 Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167:2361-2367; discussion 2367
4. Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A, Greenspan SL 2001 Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 86:2787-2791
5. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW 2002 Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599-603
6. Smith M 2004 Changes in fat and lean body mass during androgen deprivation therapy for prostate cancer. Urology 63:742-745
7. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF, Davies JS 2001 The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86:4261-4267
8. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C 2003 Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 104:195-201
9. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G 1997 Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 100:1166-1173
10. Reaven GM 2005 The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 25:391-406
11. 2005 Diagnosis and classification of diabetes mellitus. Diabetes Care 28(Suppl 1):S37-S42
12. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ 1996 Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952-957
13. Pyorala M, Miettinen H, Laakso M, Pyorala K 1998 Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation 98:398-404
14. Reaven GM 1988 Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607
15. DeFronzo RA, Ferrannini E 1991 Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194
16. Meigs JB, Wilson PW, Nathan DM, D'Agostino Sr RB, Williams K, Haffner SM 2003 Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 52:2160-2167
17. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW 1999 C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978
18. Matsuda M, DeFronzo RA 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470
19. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H 1996 A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 19:1138-1141
20. Sluiter WJ, Erkelens DW, Reitsma WD, Doorenbos H 1976 Glucose tolerance and insulin release, a mathematical approach I. Assay of the β-cell response after oral glucose loading. Diabetes 25:241-244
21. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, Shen R, Bross R, Berman N, Bhasin S 2002 The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 87:136-143
22. Eri LM, Urdal P, Bechensteen AG 1995 Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 154:100-104
23. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM 2004 Prevalence of overweight and obesity among U.S. children, adolescents, and adults, 1999-2002. JAMA 291:2847-2850